Literature DB >> 10072495

The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes.

L K Busch1, G A Bishop.   

Abstract

Latent membrane protein 1 (LMP1) is required for EBV-induced immortalization of human B cells, and expression of the protein in the absence of other viral proteins leads to an activated phenotype in B cells. It has been well documented that LMP1 causes B cells to up-regulate adhesion molecules, such as LFA-1 and ICAM-1, and coactivation molecules, such as B7-1 and CD23, as well as to activate NF-kappaB. Ligation of the endogenous B cell CD40 molecule also induces these and other activated phenotypic changes. Here, we report that expression of LMP1 also activates B cells to secrete Ig and IL-6 and rescues them from B cell receptor-mediated growth arrest analogous to CD40 signaling. Furthermore, an HLA-A2LMP1 chimeric construct demonstrates that the oligomerization of the carboxyl-terminal 200 amino acids of LMP1 is sufficient for B cell signaling. Finally, we demonstrate that LMP1 and CD40 signaling pathways interact cooperatively in inducing B cell effector functions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072495

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

2.  Transmembrane Domains Mediate Intra- and Extracellular Trafficking of Epstein-Barr Virus Latent Membrane Protein 1.

Authors:  Dingani Nkosi; Lauren A Howell; Mujeeb R Cheerathodi; Stephanie N Hurwitz; Deanna C Tremblay; Xia Liu; David G Meckes
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

3.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

4.  TRAF6 is a critical regulator of LMP1 functions in vivo.

Authors:  Kelly M Arcipowski; Laura L Stunz; Gail A Bishop
Journal:  Int Immunol       Date:  2013-10-29       Impact factor: 4.823

5.  Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins.

Authors:  M Wade; M J Allday
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

6.  The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.

Authors:  Pradeep Bangalore-Prakash; Laura L Stunz; Nurbek Mambetsariev; Amy L Whillock; Bruce S Hostager; Gail A Bishop
Journal:  Blood Adv       Date:  2017-12-18

7.  Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice.

Authors:  Anna L Peters; Laura L Stunz; David K Meyerholz; Chandra Mohan; Gail A Bishop
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

8.  TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1.

Authors:  U Schultheiss; S Püschner; E Kremmer; T W Mak; H Engelmann; W Hammerschmidt; A Kieser
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

9.  Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.

Authors:  Cornelia Brunner; Hans Wolfgang Kreth; Hans D Ochs; Volker Schuster
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

10.  Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.

Authors:  Christophe Le Clorennec; Tan-Sothéa Ouk; Ibtissam Youlyouz-Marfak; Stéphanie Panteix; Catherine-Claude Martin; Julia Rastelli; Eric Adriaenssens; Ursula Zimber-Strobl; Jean Coll; Jean Feuillard; Chantal Jayat-Vignoles
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.